KromaTiD®
Direct, Definitive Genomics
Direct, Definitive Genomics
KromaTiD™ Inc. is a biotechnology startup founded in 2007 and headquartered in the United States. The company's slogan, "Accelerating research teams from academia to large pharma with research tools and assays designed for nextgen discovery," reflects their mission to support research teams in academia, large pharmaceutical, and therapeutic companies. KromaTiD offers expert scientific support and unparalleled genomics tools and services, positioning itself as a partner for biomarker discovery, genotoxicity studies, clone screening assessment of editing-associated errors, and plasmid manufacturing.
The latest milestone for KromaTiD™ Inc. is the $4.88M Series C investment at 28 November 2023. This substantial investment demonstrates the confidence that investors have in the company's potential for growth and innovation in the biotechnology industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $4.88M | - | 28 Nov 2023 | |
| Series B | $9.10M | - | 01 Sep 2021 | |
| Venture Round | $2.00M | 1 |
|
28 Apr 2021 |
| Series A | $1.93M | - | 01 Sep 2020 | |
| Grant | Unknown | 1 | Small Business Innovation Research | 24 Aug 2020 |
No recent news or press coverage available for KromaTiD®.
We care about your data, and we'd love to use cookies make your experience better.
